These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18051783)

  • 21. [The inspection by the Danish Medical Products Agency of drug clinical trials].
    Jacobsen E; Stilbo I
    Ugeskr Laeger; 2003 Apr; 165(16):1656-8. PubMed ID: 12756822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Status of the GCP guidelines in Europe.
    Geussenhainer S
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):223-8. PubMed ID: 8361259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New Japanese GCP--from the standpoint of a sponsor].
    Ebi O
    Gan To Kagaku Ryoho; 1998 Apr; 25(5):650-62. PubMed ID: 9571962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reliability of Japanese clinical trials estimated from GCP audit findings.
    Saito K; Kodama Y; Ono S; Maida C; Fujimura A; Miyamoto E
    Int J Clin Pharmacol Ther; 2008 Aug; 46(8):415-20. PubMed ID: 18793583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current status of quality in Japanese clinical trials.
    Saito K; Kodama Y; Ono S; Mutoh M; Kawashima S; Fujimura A
    Contemp Clin Trials; 2005 Aug; 26(4):503-9. PubMed ID: 16054582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory challenges in the review of data from global clinical trials: the PMDA perspective.
    Asano K; Tanaka A; Sato T; Uyama Y
    Clin Pharmacol Ther; 2013 Aug; 94(2):195-8. PubMed ID: 23872835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The role of the Danish Medical Products Agency in clinical trials].
    Simonsen AC
    Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical development and review times for new drugs in Japan: associated factors.
    Ishibashi T; Yasuda K; Kusama M; Sugiyama Y; Ono S
    Clin Pharmacol Ther; 2010 Oct; 88(4):487-91. PubMed ID: 20739921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promoting good clinical practices in the conduct of clinical trials: experiences in the Department of Veterans Affairs Cooperative Studies Program.
    Sather MR; Raisch DW; Haakenson CM; Buckelew JM; Feussner JR;
    Control Clin Trials; 2003 Oct; 24(5):570-84. PubMed ID: 14500054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Audit of clinical trials in Argentina. Assessment of standardized operational procedures in 12 centers].
    Forti IN; Barousse AP; Bernabó JG
    Medicina (B Aires); 1991; 51(6):511-8. PubMed ID: 7476103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites.
    Zon R; Meropol NJ; Catalano RB; Schilsky RL
    J Clin Oncol; 2008 May; 26(15):2562-7. PubMed ID: 18390967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishing pan-European clinical trials: regulatory compliance and other practical considerations.
    Grienenberger A
    J Biolaw Bus; 2004; 7(4):58-63. PubMed ID: 15675097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PMDA's challenge to accelerate clinical development and review of new drugs in Japan.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Oct; 88(4):454-7. PubMed ID: 20856242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compliance with Good Clinical Practice in oncology registration trials in Japan.
    Yonemori K; Hirakawa A; Ando M; Hirata T; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
    Ann Oncol; 2011 Jun; 22(6):1451-1456. PubMed ID: 21119030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model.
    Georgias C; Grunow A; Olderog M; May A; Paulus U
    Clin Trials; 2012 Dec; 9(6):781-7. PubMed ID: 23104975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Improving the infrastructure for clinical trials in Japan].
    Nakano S
    Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):225-30. PubMed ID: 9987523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Review process of new oncology drug application in Japan--role of MD reviewer].
    Fujiwara Y
    Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):196-203. PubMed ID: 9987519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The development of good clinical practice in the EEC and in Germany.
    Anhalt E
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):217-22. PubMed ID: 8361258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.